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Abstract 
A synthetic approach to heterosubstituted cyclopent-2-en-1-ones through a robust protocol that leads to 
single 2-substituted compounds is reported. In view of a strategic design of antiviral compounds, the 
methodology was applied to substituted benzoimidazoles as neutral heterocyclic systems, as models for 
preliminary evaluation of their antiviral activities. By virtue of NMR investigations the synthetized compounds 
were structurally completely defined and the conformations were also located from DFT calculations. The 
preliminary biological tests revealed a general inactivity for most of the products with significant predictions 
for some bearing specific substituents. The results suggested possible structural changes apt to trigger the 
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Racemic and enantiomerically pure 4-oxocyclopent-2-en-1-yl acetates 1 are valuable intermediates in organic 
synthesis, often employed in the short-cut preparation of nucleoside analogues with pyrimidine and purine 
heterobases.1 The chemistry of these scaffolds have been extensively investigated and reviewed since the 
hydroxycyclopentenone moiety often appear in natural and bioactive products2 or constitutes the privileged 
starting compound for their synthesis.3 Carreira and Ruider used the racemic acetate 1 for the total synthesis 
of Hyppolachnin A.4 Recently, Reiser and co-workers have got back the chemistry of the 4-hydroxy-2-
cyclopentenone for the enantioselective synthesis of ent-Norarisateromycin5 and other enantiopure guaianes 
and pseudoguaianolides.6 Moreover, they have also applied this scaffold for the total synthesis of Sibirinone 
and other pyranone derivatives.7 In a previous work, we investigated the use of acetate 1 as a substrate for 
the functionalization with uracil, thymine, 6-chloropurine and some adenines in a fast-track to nucleoside 
analogues. We found that the expected 4-heterosubstituted products could be obtained along with the 
isomeric 2-heterosubstituted compounds as minor components. Samples of selected products were evaluated 
for their antiviral activity in a primary screening against a variety of viruses belonging to different classes. One 
of them, belonging to the family of the 4-substituted cyclopentenones of type 2, was found to be highly active 
against HPV. Others, belonging to the family of the 2-substituted cyclopentenones of type 3, were found to be 
moderately active against Punta Toro virus and Rift Valley fever virus (Scheme 1). The protocol for their 
synthesis stands on a simple nucleophilic substitution of the acetate group of the cyclopentenone scaffold 1 












Scheme 1. Synthesis of 4-substituted- and 2-substituted-cyclopentenone derivatives. 
 
On pursuing the investigations on the synthesis of nucleoside analogues based on the cyclopentenone 
scaffold, two elements were the focus of our subsequent researches. The first one regards the selectivity of 
the substitution process; upon adding the 4-oxocyclopent-2-en-1-yl acetate 1 at 0 °C to solutions of the 
heterobase anions in anhydrous acetonitrile and leaving under stirring for 3 hours, mixtures of the two 
regioisomeric products 2 and 3 were obtained. We have demonstrated that these compounds have different 
biological activity as antivirals. Now, our aim is to obtain single regioisomers, introducing a modified protocol 
apt to govern the selectivity outcome. In particular, our focus is to obtain the 2-substituted cyclopentenone 
derivatives that have previously displayed only modest antiviral activities in order to improve their 
performances by specific structural changes. Second, previously we have investigated purine and pyrimidine 
heterobases but, in theory, other heterocyclic compounds could be of remarkable interest for their potential 
biological activities, properly tuned by introducing of different substituents and/or heteroatoms and properly 
selected from the wide family of heterocyclic compounds. 
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Here, we propose our design strategy by using benzoimidazoles derivatives bearing a variety of substituents 
that represent simple heterocyclic models, reactive enough as nucleophiles and suitable for locating structural 
changes or derivatization pathways. So, the aim is to develop a step-by-step tuning of a heterocycle structure, 
on the one hand, and, of the cyclopentenone moiety structure, on the other hand, in order to get the required 
information on the structure-activity relationship (SAR) for these types of molecules, with the help of suitable 
and corroborating biological evaluations. 
 
 
Results and Discussion 
 
The racemic 4-oxocyclopent-2-en-1-yl acetate9 (±)-1 was obtained by acetylation reaction10 of the 
corresponding 4-hydroxy-2-cyclopentenone according to known procedures.5,11 
The coupling reactions were conducted by in situ generation of the conjugated bases of the commercially 
available substituted benzoimidazole heterocycles 4a-d with NaH 95% in dry acetonitrile (Scheme 2). The 
benzoimidazole anions generation required the use of a Schlenk tube apparatus under vacuum, stirring the 
suspension for 15 minutes at room temperature. Afterwards, the acetonitrile solution of the cyclopentenone 
acetate 1 was added and the reactions were left under stirring in inert atmosphere overnight at room 
temperature. Quenching was performed by pouring the mixtures in ice mixed with NaCl/NH4Cl 1:3. Extraction 
with DCM allowed for the obtaining of organic phases that were dried over anhydrous Na2SO4. Residues were 
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Scheme 2. Synthesis of 2-benzoimidazole-cyclopentenone derivatives 5 and 6. 
 
In order to get evidence of possible electronic effects on the reaction outcome, the selected 
benzoimidazoles 4a-d, which contain substituents with different electron-donor or electron-withdrawing 
capacities. Compound 7 containing the substituent-free benzoimidazole ring was also synthesized for 
comparison purposes. From the reaction mixtures 2-substituted cyclopentenones derivatives were obtained 
selectively, as mixtures of compounds 5a-d and 6a-d, derived from different orientation in the coupling 
reaction of the benzoimidazole rings, not separable by any chromatographic technique at this step of the 
designed protocol. Compounds 5a-d are obtained in fact from the addition of the benzoimidazole at the N1 
nitrogen atom while compounds 6a-d at the N3 nitrogen atom, since they exist in two equilibrium forms when 
react with NaH. No 4-substituted cyclopentenone derivatives (type 2 of Scheme 1) were isolated or even 
detected in the crude reaction mixtures. The synthetic method leads selectively to the 2-substituted 
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compounds (type 3 of Scheme 1). Compounds 5a-d and 6a-d were obtained as inseparable mixtures of 
regioisomers, as every attempt to separated them with chromatographic techniques failed due to the low 
level of structural differentiation between the single pairs. Table 1 reports chemical yields, physical data and 
the relevant IR bands of the synthetized adducts. The yields are good in all the cases. They never reach 
quantitative values due to partial decomposition of the starting acetate compound 1. It is known, in fact, that 
it is unstable upon standing at room temperature: decomposition starts in a couple of days to afford another 
unstable compound, the cyclopentadienenone (for mechanism, vide infra). From the structural point of view, 
the IR spectra clearly report the presence of the carbonyl C=O groups and the C=N bands referred to the 
imidazole moieties and the values are found at the expected wave numbers for these type of compounds. 
 
Table 1. Chemical yields, physical data and relevant IR bands of compounds 5a-d, 6a-d and 7 (Scheme 2) 
Entry 5/6 Yield M.p. IR (cm-1)b 
  (%) (°C)a νC=O νC=N 
1 a 53 205-210 1686 1607 
2 b 60 215-219 1674 1595 
3 c 51 210 (dec.) 1684 1607 
4 d 67 194-200 1692 1590 
5 7 70 >250 1678 1581 
 
aFrom diisopropyl ether with few drops of ethanol. bNujol mulls. 
 
However, the structural assignment remained an open problem and was adequately solved even in the 
presence of mixtures of compounds by NMR experiments by collecting the 1H NMR spectra in deuterated 
DMSO and analyzing the signals with the help of further experiments, such as COSY and NOESY and upon 
comparison with the single compound spectrum obtained from the reaction with benzoimidazole (adduct 7).  
Table 2 reports the relevant signals as attributed according to the observation hereby exposed. All the 
spectra of the products and double resonance experiments spectra are given in the Supplementary Material 
(SM). Compounds 5a-d, bearing the substituent R on the C5 of the benzoimidazole ring, are the minor 
components of the mixtures where the ratios range from 1:1.2 for compounds 5/6a,c to 1:2 for the nitro 
derivatives 5/6d up to 1:4 for the chloro derivative 5/6b. They showed the more deshielded chemical shifts of 
the CH=N of the benzoimidazole ring with respect to the regioisomers 6a-d, while some order inversions are 
found for the signals corresponding to the olefinic =CH protons. The aromatic signals of the benzenic part of 
the heterocyclic moiety deserve the typical multiplicity relative to two protons with an ortho coupling, being 
one of them coupled with the third proton through a meta coupling constant (not always detectable). Protons 
HC in adducts 5a-c are more deshielded with respect to all the other signals presumably because of the 
proximity with the carbonyl group of the cyclopentenone moiety (free rotation around the NHET-C= bond) with 
a single exception of 5d, where the nitro group displays deshielding effects on the other adjacent protons. The 
same happens for the protons HC' of compounds 6a,b,d with the single exception of 5c, where the methoxy 
group displays shielding effects on the other adjacent protons. The chemical shifts of the benzoimidazole 7 
closely resemble those of the methyl derivatives and confirm that the HC proton is the most deshielded among 
the aromatic protons because of the proximity with the carbonyl group of the cyclopentenone moiety. 
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Entry 5a NMR δ, CDCl3 Minor comp. 6a NMR δ, CDCl3 Major comp. 
  CH=N HX HA HB C=CH  CH=N HA' HC' HB' C=CH 
1 ab 8.72 (s) 7.86 (d) 7.60 (s) 7.24 (t) 6.64 (s) ab 8.69 (s) 7.66 (d) 7.81 (s) 7.24 (t) 6.67 (s) 
2 bc 8.90 (s) 8.06 (d) 7.91 (d) 7.45 (d) 6.67 (s) bc 8.87 (s) 7.82 (d) 8.11 (d) 7.45 (d) 6.75 (s) 
3 cd 8.76 (s) 7.90 (d) 7.36 (d) 7.02 (d) 6.59 (s) cd 8.67 (s) 7 68 (d) 7.34 (d) 7.00 (d) 6.67 (s) 
4 de 9.17 (s) 8.02 (d) 8.72 (d) 8.27 (m) 6.80 (s) de 9.10 (s) 8.27 (m) 8.65 (bs) 8.27 (m) 6.78 (s) 
5 7f 8.83 (s) 8.03 (m) 7.81 (m) 7.43 (m) 6.65 (s)       
 
aThe reaction was conducted in anoxic conditions. bAt 2.54 and 3.37 δ the CH2CH2 moiety is found for both 5a 
and 6a. The Methyls are also found at 2.46 and 2.50 δ.  cAt 2.55 and 3.34 δ the CH2CH2 moiety is found for both 
5b and 6b. dOther signals; 5c, δ: 3.84 (s, MeO). 6c, δ: 3.89 (s, MeO). At 2.53 and 3.36 δ the CH2CH2 moiety is 
found for both 5c and 6c. eAt 2.58 and 3.42 δ the CH2CH2 moiety is found for both 5d and 6d. fAt 2.55 and 3.39 
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Scheme 3. Synthesis of 2-benzoimidazole-cyclopentenone derivatives 5 and 6: mechanism. 
 
The attributions given in Table 2 were corroborated through COSY and NOESY experiments performed on 
the methoxy derivatives 5/6c that showed more separated signals with respect to the other compounds and 
similar intensities, thus allowing to perform efficiently these double resonance experiments. In particular in 
the NOESY experiment, the proton HC' of 6c at 7.34 δ gives a NOE spot with the methoxy group at 3.89 δ as 
well as with the olefinic proton at 6.67 δ; this latter gives also a NOE spot with the CH=N proton at 8.67 δ. On 
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the other hand, in the case of compound 5c, the doublet at 7.90 δ gives a single NOE spot with the olefinic 
proton at 6.59 δ; this latter also spatially interacts with the CH=N proton at 8.76 δ. On the basis of these 
observations all the correlations for the structure assignments for the other compounds derive consequently. 
From the mechanistic point of view the structures of compounds 5a-d, 6a-d and 7 rely on a leaving group (LG)-
elimination-addition-isomerization process that starts from the acetate 1 (Scheme 3), affording the allyl cation 
88' that, under the reported experimental conditions, adds the benzoimidazole anions 4a-d to give the not-
isolable adducts 9a-d. These latters undergo C=C double bond isomerization to the final products 5/6a-d. The 
proposed mechanism has been previously demonstrated upon starting from enantiomerically enriched 
acetate 1 that could not afford any optically active products but just racemic compounds, as a definitive 
confirm that the allyl cation of type 8 is involved in the product formation and that a SN2 type nucleophilic 
substitution can be discarded among the possible reaction routes.8 
Another key point about the synthetized compounds regards their thermal and photochemical stability. 
We have investigated this point taking into account previous observation8 and in view of novel opportunities 
for a further functionalization of the products at hand, useful for SAR studies that potentially require structural 
changes. Compounds 5/6a-d were heated at refluxing methanol for several hours and the stability of the 
compounds monitored by TLC. After 24h, compounds 5/6a-d were found unchanged and the structure 
resistance upon moderate heating was confirmed by 1H NMR spectra that gave the same signals as the original 
samples. On the other hand, when heated in the presence of bases (e.g. triethylamine) compounds 5/6a-d 
undergo decomposition leaving a detectable and isolable benzoimidazole residues and loosing the 
cyclopentenone moiety, reasonably as cyclopentadieneone as leaving group, as previously suggested.8 
We have submitted samples of the compounds 5/6a-d to exposure to UV light at 254, 310 and 400 nm for a 
couple of hours to test their photostability. Even in these cases we noted the release of the benzoimidazolic 
moieties that could be detected as the only structures reasonably attributable to the residues left after the 
photochemical processes, being the cyclopentenone moiety completely lost. 
In summary, we can conclude that these structures are thermally (in the presence of bases) and 
photochemically labile and, unless with the help of further structural modifications able to stabilize them, 
hardly employed in experimental conditions that activate the loss of the cyclopentenone moiety. 
For the antiviral evaluation, samples of the synthetized compounds compounds were sent to the NIAID (NIH, 
USA)12 for in-vitro tests against a variety of viruses for a primary screening study. Products 5/6a-d were tested 
against the Herpesviridae family, Varicella-Zoster virus, (VZV), from the Hepatic virus HBV, Respiratory Viruses 
such as Influenza A virus H1N1 (IV/H1N1), Adenovirus-5 (AD5), from the Togavidae family, Chikungunya virus 
(CV), from the Flaviridae group, Yellow Fever Virus (YFV), from the Bunyaviridae family, Punta Toro Virus (PTV), 
and from the Papovaviridae the Human Papilloma Virus (HPV).  
Compounds 5/6a-d were found inactive against VZV; although the CC50 is >150 (identical to Aciclovir used 
as reference compound), the EC50 was >150, enormously higher than the reference. Similarly, compounds 
5/6a-d were found inactive against HBV; lamivudine (used as reference compound) has an EC50 = 0.041 
compared with that of 5/6a-d >100. The primary antiviral data of compounds 5/6a-d against IV/H1N1 and AD5 
were compared with the relative reference compounds and show that compounds 5/6a,b,d were found 
inactive while 5/6c that bears a methoxy substituent showed a modest activity although the EC50 is more than 
10 times that of Ribavirin. On the other hand, the activities against AD5 were disappointing. Table 3 gathers 
the EC50, CC50 and SI50 values (µg/mL) obtained in the in vitro tests against the reported viruses for the 
compound 5/6c, only. A complete data table for all the compounds can be found in the SM. 
Finally, the primary tests against YFV and CV demonstrated a total inefficacy of all the compounds against 
these viruses as well as of the tests against PTV and HPV. 
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On the basis of these results we have focused our attention to the possible two conformers of the 
benzoimidazole-cyclopentenone structures and the methoxy derivatives for planning further derivatizations 
apt to strongly modify the structures at different positions of the entire skeleton, triggering a more effective 
biological activity. We have located the more stable optimized conformation of adduct 7 and those of the two 
methoxy derivatives 5c and 6c at the B3LYP(6-31G)(d) level.13 
 
Table 3. Primary antiviral activities of compounds 5a-d and 6a-d against IV/H1N1 
Entry Compound Drug Assay Name EC50 CC50 SI50 
  (Cytopathic eff.)    
  IV/H1N1a    
1 5/6c Visual 15 >100 >6.7 
  Neutral Red 25 >100 >4.0 
  IV/H1N1a    
2 Ribavirinb Visual 1.2 >320 >270 
  Neutral Red 1.4 >320 >270 
 
aDrug conc. Range 0.1-100 µg/mL (vehicle, DMSO). bControl conc. Range 0.32-320 µg/mL. cDrug conc. Range 
0.048-150 µM (vehicle, DMSO). dControl conc. Range 0.048-150 µM. 
 
Figure 1 shows the optimized structures with relative energies. The two types of conformers have been 
identified as sin and anti on the basis of the relative position of the cyclopentenone carbonyl group and the H-
C=N proton of the imidazole ring. Conformer 7sin was found more stable than 7anti by 1.91 kcal/mol and 
shows a stabilizing intramolecular H-bonding between the H-C=N proton of the imidazole ring and the 
cyclopentenone carbonyl group at a distance of 2.34Å. The intramolecular H-bonding keeps the 
benzoimidazole ring of the 7sin conformer slightly tilted by 26.4° with respect to the cyclopentenone average 
plane. Conformer 7anti does not gain any stabilizing effect through H-bonding and the two rings are tilted by 
44.4°. 
Moving to the methoxy derivatives that showed the most promising antiviral activities against the 
IV/H1N1, the comparison of the conformers offer a similar picture. Conformer 5csin is more stable than 5canti 
by 1.99 kcal/mol and stabilized by an intramolecular H-bonding (2.33Å) with the two sings on different planes 
(dihedral angle 25.4°). Conformer 6csin is more stable than 6canti by 1.62 kcal/mol and stabilized by an 
intramolecular H-bonding (2.34Å) with the two sings on different planes (dihedral angle 36.1°). The absence of 
a stabilizing intramolecular H-bonding in the comformers of type anti brings the two cyclic moieties of the 
molecules (cyclopentenone and methoxy-benzoimidazole) to be tilted by larger dihedral angles (up to 50°). 
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Figure 1. Optimized conformers of benzoimidazole-cyclopentenone 7 and methoxy derivatives 5c and 6c. 
Values in Å indicate the H-bonding distances. 
 
These conformational pictures somewhat suggest scope and limitations in the modification and/or 
derivatization of compounds 5/6 and 7. Three main synthetic pathways can be considered to tune the 
biological activities and to solve the regioselectivity outcome relative to the heterocyclic moiety and are 
sketched in Scheme 4. The C=C double bond, the carbonyl group of the cyclopentenone moiety and the 
substituent on the benzoimidazole ring can be the three sites where synthetic modifications are possible. The 
most intriguing is represented by the functionalization of the C=C double bond through 1,3-dipolar 
cycloaddition of stable nitrile oxides (Scheme 4, path a) and it also represents a challenging task since it would 
furnish a regioisomeric mixture of cycloadducts of type 8A,B having the bicyclic structure of 6a-(1H-
benzo[d]imidazol-1-yl)-3a,4,5,6a-tetrahydro-6H-cyclopenta[d]isoxazol-6-ones, a class of heterocyclic 
substituted cyclopenta-isoxazolones often found in natural products and biologically active compounds.14 The 
potential obstacle in performing these reactions could be the steric availability of the C=C double bond. In H-
bonded constrained structures, this could be detrimental for the cycloaddition reaction success, which is 
sterically demanding. On the other hand, the activation of the anti conformations by interrupting the 
intramolecular H-bonds (solvent and temperature effects) could offer a solution to get the final goal. 
Moreover, these structures nicely resemble those of hexahydropentalen-1(2H)-one compounds that are useful 
scaffolds for the synthesis of sesquiterpenes.15,16 
 
7sin                                  7anti 
5csin                                       5canti 
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Scheme 4. Strategies for the synthetic elaboration of 2-benzoimidazole-cyclopentenone derivatives 5 and 6. 
 
On the other side, a chemical modification of the substituent on the phenyl ring of the benzoimidazole 
moiety as well as the derivatization of the carbonyl group (Scheme 4, paths b and c) will determine potential 
key point to tune properly the biological performances of the designed compounds.17,18 If the changes 
accordingly path b seem to be highly risky and affect directly the reactivity of the benzene ring, the 
functionalization of the carbonyl group (path c) again calls into question the role of the intramolecular H-
bonding to let the carbonyl group free for nucleophilic addition reactions, as an example. 
Before starting to investigate in full these opportunities, preliminary results indicate that the reaction between 
the benzoimidazole derivative 7 and mesitonitrile oxide can afford the expected regioisomeric cycloadduct of 
type 8 (Scheme 4, a-b-c = Mes-C=N-O). Being mesitonitrile oxide a typical stable nitrile oxide that operates in 
the absence of any kind of base (detrimental for the dipolarophile) it will be one of the 1,3-dipole of choice for 
conducting these studies for the synthesis of cyclopenta[d]isoxazol-6-one structures, to be evaluated for their 
potential biological activities.19-21 As a final remark, these structural changes and derivatizations will 
definitively help in the separation of the regioisomeric compounds of type 5 and 6, whose biological 





In conclusion, we have reported a selective approach to 2-heterosubstituted cyclopent-2-en-1-ones through a 
valuable protocol that avoids the presence of side regiosiomeric compounds. The methodology has been 
applied to substituted benzoimidazole as model heterocyclic systems in view of future introduction of other 
compounds as well as suitable for further transformations as function of the tested biological activity as 
antivirals. By virtue of NMR investigations the synthetized compounds were structurally completely defined 
and the conformations were also located from theoretical investigation with DFT calculations. The preliminary 
biological in vitro tests revealed a general inactivity for most of the products with significant indication for 
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some of them bearing specific substituents. These results immediately suggested possible structural changes 





General. All melting points are uncorrected. Elemental analyses were done on a C. Erba 1106 elemental 
analyzer. IR spectra (Nujol mulls for solids) were recorded on an FT-IR Perkin-Elmer RX-1. 1H- and 13C-NMR 
spectra were recorded on a Bruker AVANCE 400 and 300 in the specified deuterated solvents. Chemical shifts 
are expressed in ppm from internal tetramethylsilane (δ). Column chromatography and tlc: silica gel 60 (0.063-
0.200 mm) (Merck); eluent cyclohexane/ethyl acetate from 9:1 to 5:5. MPLC chromatographic separations 
were performed on a Biotage Flash Master Personal apparatus; eluent cyclohexane/ethyl acetate from 9:1 to 
5:5. Furfuryl alcohol, benzoimidazole and substituted benzoimidazoles were purchased from Sigma-Aldrich. All 
other reagents and solvents were purchased from Sigma-Aldrich and Alfa-Aesar and used without any further 
purification. 
 
Synthesis of 2-(5-substituted-1H-benzo[d]imidazol-1-yl)cyclopent-2-en-1-ones (5a-d) and 2-(6-substituted-
1H-benzo[d]imidazol-1-yl)cyclopent-2-en-1-ones (6a-d); (general procedure). An excess of 5-substituted 
benzoimidazoles 4a-d (1.5 equiv.) were dissolved in 8 mL of anhydrous acetonitrile and 1.7 equiv. NaH 95% 
were added portionwise under stirring in a Schlenk tube at room temperature, applying mechanical vacuum 
until complete evolution of hydrogen gas. After 15 minutes, 1 g (7.14 mmol) of the 4-hydroxy-2-
cyclopentenone acetate (±)-1 was dissolved in the minimum amount of anhydrous acetonitrile and added to 
the solution under stirring. The reactions are left under stirring at room temperature overnight. The reactions 
were quenched with ice mixed with NaCl/NH4Cl 1:3 and the water phase extracted with DCM. The organic 
phases were dried over Na2SO4 and, upon evaporation of the solvent, the residues were submitted to 
chromatographic separation to isolate the purified products 5/6a-d. 
5/6a (0.8 g, 53%) as a straw yellow solid; [Found: C, 73.6; H, 5.7; N, 13.2%. C13H12N2O requires C, 73.56; H, 
5.70; N, 13.20%]; Rf (100% MeOH) 0.59; νmax (nujol) 1686, 1607 cm−1; δH (300 MHz DMSO) 2.46 (3H, s, CH3), 
2.50 (3H, s, CH3), 2.54 (2H, m, CH2), 3.37 (2H, m, CH2), 6.64 (1H, s, CH=), 6.67 (1H, s, CH=), 7.24 (1H+1H, t, J 7 
Hz, arom.), 7.60 (1H, s, arom.), 7.66 (1H, d, J 9 Hz, arom.), 7.81 (1H, s, arom.), 7.86 (1H, d, J 9.0 Hz, arom.), 8.69 
(1H, s, CH=N), 8.72 (1H, s, CH=N); δC (75.0 MHz, DMSO) 205.8, 205.7, 165.6, 165.5, 144.9, 142.7, 142.6, 142.2, 
134.8, 133.6, 132.0, 129.8, 126.1, 125.5, 120.2, 119.9, 113.7, 113.6, 113.5, 113.2, 33.4, 28.1, 28.0, 21.3, 20.9. 
5/6b (1.0 g, 60%) as a straw yellow solid; [Found: C, 62.0; H, 3.9; N, 12.0%. C12H9N2OCl requires C, 61.95; H, 
3.90; N, 12.04%]; Rf (100% MeOH) 0.61; νmax (nujol) 1674, 1618 cm−1; δH (300 MHz DMSO) 2.55 (2H, m, CH2), 
3.34 (2H, m, CH2), 6.67 (1H, s, CH=), 6.75 (1H, s, CH=), 7.45 (1H+1H, d, J 7 Hz, arom.), 7.82 (1H, d, J 9 Hz, arom.), 
7.91 (1H, s, arom.), 8.11 (1H, s, arom.), 8.87 (1H, s, CH=N), 8.90 (1H, s, CH=N); δC (75.0 MHz, DMSO) 205.3, 
164.7, 143.4, 142.9, 132.0, 129.1, 124.4, 124.1, 121.2, 119.6, 114.6, 114.4, 114.1, 113.2, 33.1, 27.6. 
5/6c (0.8 g, 51%) as a light brown solid; [Found: C, 68.4; H, 5.3; N, 12.3%. C13H12N2O2 requires C, 68.41; H, 5.30; 
N, 12.27%]; Rf (100% MeOH) 0.60; νmax (nujol) 1684, 1607 cm−1; δH (300 MHz DMSO) 2.53 (2H, m, CH2), 3.36 
(2H, m, CH2), 3.84 (3H, s, CH3O), 3.89 (3H, s, CH3O), 6.59 (1H, s, CH=), 6.67 (1H, s, CH=), 7.00 (1H, d, J 2 Hz, 
arom.), 7.02 (1H, d, J 2 Hz, arom.), 7.34 (1H, d, J 2 Hz, arom.), 7.36 (1H, d, J 2 Hz, arom.), 7.68 (1H, d, J 8 Hz, 
arom.), 7.90 (1H, d, J 8 Hz, arom.), 8.67 (1H, s, CH=N), 8.76 (1H, s, CH=N); δC (75.0 MHz, DMSO) 205.4, 205.3, 
165.1, 165.0, 157.2, 156.4, 145.4, 142.8, 141.3, 138.3, 132.1, 125.6, 120.4, 113.6, 113.5, 113.1, 112.9, 112.5, 
103.0, 987.2, 55.5, 55.2, 33.0, 27.7, 27.5. 
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5/6d (1.2 g, 67%) as a brown solid; [Found: C, 59.3; H, 3.7; N, 17.3%. C12H9N3O3 requires C, 59.26; H, 3.73; N, 
17.28%]; Rf (100% MeOH) 0.58; νmax (nujol) 1692, 1590 cm−1; δH (300 MHz DMSO) 2.58 (2H, m, CH2), 3.42 (2H, 
m, CH2), 6.78 (1H, s, CH=), 6.80 (1H, s, CH=), 8.02 (1H, d, J 9 Hz, arom.), 8.27 (3H, s, arom.), 8.65 (1H, bs, 
arom.), 8.71 (1H, d, J 2 Hz, arom.), 9.10 (1H, s, CH=N), 9.17 (1H, s, CH=N); δC (75.0 MHz, DMSO) 205.7, 205.6, 
165.0, 164.9, 148.8, 147.7, 146.4, 144.5, 144.2, 144.1, 135.9, 131.2, 120.9, 119.9, 119.6, 116.1, 116.06, 115.8, 
114.3, 109.9, 33.7, 33.6, 28.1, 28.05. 
Synthesis of 2-(1H-benzo[d]imidazol-1-yl)cyclopent-2-en-1-one (7). An excess of benzoimidazole (1.5 equiv.) 
was dissolved in 8 mL of anhydrous acetonitrile and 1.7 equiv. NaH 95% were added portionwise under stirring 
in a Schlenk tube, applying mechanical vacuum until complete evolution of hydrogen gas. After 15 minutes, 1 
g (7.14 mmol) of the 4-hydroxy-2-cyclopentenone acetate (±)-1 was dissolved in the minimum amount of 
anhydrous acetonitrile and added to the solution under stirring. The reaction is left under stirring at room 
temperature overnight. The reaction was quenched with ice mixed with NaCl/NH4Cl 1:3 and the water phase 
extracted with DCM. The organic phases were dried over Na2SO4 and, upon evaporation of the solvent, the 
residue was submitted to chromatographic separation to isolate the purified product 7. 
7 (1.0 g, 70%) as a light brown solid; [Found: C, 72.7; H, 5.1; N, 14.1%. C12H10N2O requires C, 72.71; H, 5.09; N, 
14.13%]; Rf (100% MeOH) 0.62; νmax (nujol) 1678, 1581cm−1; δH (300 MHz DMSO) 2.55 (2H, m, CH2), 3.39 (2H, 
m, CH2), 6.65 (1H, s, CH=), 7.43 (1H+1H, m, arom.), 7.81 (1H, m, arom.), 8.03 (1H, m, arom.), 8.83 (1H, s, 
CH=N); δC (75.0 MHz, DMSO) 205.3, 165.2, 144.2, 142.4, 131.4, 124.5, 123.8, 120.0, 113.5, 113.3, 33.0, 27.7. 
 
Biological tests 
Antiviral assays. The National Institute of Allergy and Infectious Diseases (NIAID) provides free and 
confidential services for suppliers, who are interested in submitting compounds to be evaluated for antiviral 
activity. Tested compounds were delivered in standard DMSO solutions. The methods applied for the different 
assays can be found at the URL via the internet at http://niaid-aacf.org. 
Compounds 5/6a-d were tested against the Herpesviridae family, Varicella-Zoster virus, (VZV, virus strain, 
Ellen, cell line, HFF), from the Hepatic virus HBV (virus strain ayw; cell line 2.2.15), Respiratory Viruses such as 
Influenza A virus H1N1 (IV/H1N1, virus strain, InfluenzaA/California/7/2009; cell line, MDCK), Adenovirus-5 
(AD5, Adenoid75, virus strain; cell line, HFF), from the Togavidae family, Chikungunya virus (CV, virus strain, 
S27/VR-64, cell line, Vero 76), from the Flaviridae group, Yellow Fever Virus (YFV, virus strain, 17D; cell line, 
Huh7), from the Bunyaviridae family, Punta Toro Virus (PTV, virus strain, Adames; cell line, Vero 76), and from 
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1H, 13C, COSY and NOESY spectra, Cartesian coordinates of calculated structures are given in the 
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